nach oben

Applied Health Economics and Health Policy

Erschienen in:

01.12.2005 | Original Research Article

The incremental cost effectiveness of withdrawing pulmonary artery catheters from routine use in critical care

verfasst von: Katherine Stevens, Christopher McCabe, Carys Jones, Joanne Ashcroft, Sheila Harvey, Kathy Rowan

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to conduct an economic evaluation to identify any differences in the expected costs and outcomes between patients treated with pulmonary artery catheters (PACs) and those without, in order to better inform healthcare decision makers.

Method

The evaluation was carried out alongside a clinical trial investigating the use of PACs in intensive care units (ICUs) in the UK. It was conducted from the perspective of the UK NHS, in which PACs are an established intervention. Treating patients without using a PAC was characterised as the new intervention.

The primary outcome measure was QALYs. The secondary outcome measure was hospital mortality. NHS costs per patient were calculated for the financial year 2002/03.

The bootstrap method was used to characterise the uncertainty of the results and to construct cost-effectiveness acceptability curves.

Results

The cost per QALY and per life gained from the withdrawal of PACs were £2892 and £21 164, respectively.

Conclusion

The results of this study indicate that withdrawal of PACs from routine clinical use in ICUs within the NHS would be considered cost effective in the current decision-making climate.

¹Strictly there are other measures; however, the QALY is the most common.

²Conventional frequentist analysis often uses the confidence interval to characterise uncertainty. However, a 95% confidence interval does not tell you a range within which you are 95% certain the true value lies. Rather, it tells you that if you were to repeat the experiment 100 times and calculate the confidence interval on each occasion, in 95 of those analyses the true value would lie within the calculated range and on five occasions it would not. It provides no information about whether the results you are analysing are one of the 95 or one of the 5. In contrast to this, the Bayesian approach to characterising uncertainty, which is used in this study, tells you the degree of belief or probability that something is true.

Guyatt G. A randomized control trial of right-heart catheterization in critically ill patients: Ontario Intensive Care Study Group. J Intensive Care Med 1991; 6(2): 91–5PubMed

Rhodes A, Cusack RJ, Newman PJ, et al. A randomised, controlled trial of the pulmonary artery catheter in critically ill patients. Intensive Care Med 2002; 28(3): 256–64PubMedCrossRef

Richard C, Warszawski J, Anguel N, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290(20): 2713–20PubMedCrossRef

Isaacson IJ, Lowdon JD, Berry AJ, et al. The value of pulmonary artery catheter and central venous monitoring in patients undergoing abdominal aortic reconstructive surgery: a comparative study of two selected, randomized groups. J Vasc Surg 1990; 12(6): 754–60PubMedCrossRef

Joyce W, Provan JL, Ameli FM, et al. The role of central haemodynamic monitoring in abdominal aortic surgery: a prospective randomised study. Eur J Vasc Surg 1990; 4(6): 633–6PubMedCrossRef

Pearson KS, Gomez MN, Moyers JR, et al. A cost/benefit analysis of randomized invasive monitoring for patients undergoing cardiac surgery. Anesth Analg 1989; 69(3): 336–41PubMedCrossRef

Bender JS, Smith-Meek MA, Jones CE. Routine pulmonary artery catheterization does not reduce morbidity and mortality of elective vascular surgery. Ann Surg 1997; 226(3): 229–37PubMedCrossRef

Berlauk JF, Abrams JH, Gilmour IJ, et al. Preoperative optimization of cardiovascular hemodynamics improves outcome in peripheral vascular surgery: a prospective, randomized clinical trial. Ann Surg 1991; 214(3): 289–99PubMedCrossRef

Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348(1): 5–14PubMedCrossRef

10.

Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94: 1176–86PubMedCrossRef

11.

Valentine RJ, Duke ML, Inman MH, et al. Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. J Vasc Surg 1998; 27: 203–12PubMedCrossRef

12.

Connors Jr AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996 Sep; 276: 889–97PubMedCrossRef

13.

Pulmonary Artery Catheter Consensus Conference Participants. Consensus statement. Pulmonary Artery Catheter Conference. Crit Care Med 1997; 25: 910–25CrossRef

14.

Dalen JE, Bone RC. Is it time to pull the pulmonary artery catheter? JAMA 1996; 276(6): 916–8PubMedCrossRef

15.

Soni N. Swan song for the San-Ganz catheter? The use of pulmonary artery catheters probably needs re-evaluation: but should they be banned? BMJ 1996; 313: 763–4PubMedCrossRef

16.

Reinhart K, Radermacher P, Sprung CL, et al. PA catheterization: quo vadis? Do we have to change the current practice with this monitoring device? Intensive Care Med 1997; 23: 605–9PubMedCrossRef

17.

Weinstein MC. Should physicians be gatekeepers of medical resources? J Med Ethics 2001; 27: 268–74PubMedCrossRef

18.

Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366: 472–7PubMedCrossRef

19.

Drummond MF, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

20.

Tarn TYH, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10(4): 5–15

21.

National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal [online]. Available from URL: http://www.nice.org.uk/page.aspx?.o=201974 [Accessed 2005 Jul 26]

22.

NHS reference costs. Department of Health [online]. Available from URL: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSReferenceCosts/fs/en [Accessed 2004 Sep 1]

23.

The Office for National Statistics [online]. Available from URL: http://www.gad.gov.uk/Life_Tables/Interim_Life_Tables.htm [Accessed 2005 Dec 20]

24.

Kind P, Hardman G, Macran S. UK population norms for EQ-5D. CHE discussion paper no.: 172. York: The University of York; 1999 Nov

25.

Wright JC, Penderleith L, Ridley SA. Long term survival following intensive care: sub-group analysis and comparison with the general population. Anaesthesia 2003; 58: 637–42PubMedCrossRef

26.

HM Treasury. The green book. London: HM Treasury, 2003 [online]. Available from URL: http://greenbook.treasury.gov.uk/ [Accessed 2004 Sep 14]

27.

Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996

28.

Chaudhary MA, Stearns SC. Estimating confidence intervals for cost effectiveness ratios: an example from a randomised trial. Stat Med 1996; 14: 1447–58CrossRef

29.

Efron B, Tisbshirani R J. An introduction to the bootstrap. New York: Chapman and Hall, 1993

30.

Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723–40PubMedCrossRef

31.

Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309–19PubMedCrossRef

32.

McCabe CJ, Payne JN, Pickin DM, et al. For NHS centre reviews and dissemination. Cholesterol and coronary heart disease: screening and treatment. Eff Health Care 1998; 4(1): 1–16

33.

Niskanen M, Kari A, Haonen P. Five-year survival after intensive care: comparison of 12,180 patients with the general population. Crit Care Med 1996 Dec; 24(12): 1962–7PubMedCrossRef

34.

Palmer S, Smith PC. Incorporating options values into the economic evaluation of healthcare technologies. J Health Econ 2000; 19: 755–66PubMedCrossRef

35.

Briggs AH, O’Brien BJ. The death of cost minimization analysis. Health Econ 2001; 10: 179–84PubMedCrossRef

36.

Claxton C, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002; 360: 711–5PubMedCrossRef

Titel: The incremental cost effectiveness of withdrawing pulmonary artery catheters from routine use in critical care
verfasst von: Katherine Stevens
Christopher McCabe
Carys Jones
Joanne Ashcroft
Sheila Harvey
Kathy Rowan
Publikationsdatum: 01.12.2005
Verlag: Springer International Publishing
Erschienen in: Applied Health Economics and Health Policy / Ausgabe 4/2005
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI: https://doi.org/10.2165/00148365-200504040-00008

Springer Medizin

Abstract

Objective

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK

Acknowledgement

The Australian health policy changes of 1999 and 2000

Should patients have a greater role in valuing health states?

How to present the business case for healthcare quality to employers

What value health?